Jpmorgan Chase & CO Equillium, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Equillium, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 41 shares of EQ stock, worth $38. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41
Previous 43
4.65%
Holding current value
$38
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding EQ
# of Institutions
26Shares Held
11.3MCall Options Held
0Put Options Held
0-
Decheng Capital Management Iii (Cayman), LLC4.45MShares$4.18 Million1.82% of portfolio
-
Decheng Capital LLC Menlo Park, CA4.45MShares$4.18 Million0.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA842KShares$791,4310.0% of portfolio
-
Cota Capital Management, LLC San Francisco, CA562KShares$528,541100.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny261KShares$245,7160.0% of portfolio
About Equillium, Inc.
- Ticker EQ
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,352,100
- Market Cap $32.3M
- Description
- Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...